Interaction between cytokines and sCD40L in patients with stable and unstable coronary syndromes

European Journal of Clinical Investigation

Volumn 37, Issue 8, 2007, Pages 623-628

  Tousoulis, D ^a   Antoniades, C ^a   Nikolopoulou, A ^a   Koniari, K ^a   Vasiliadou, C ^a   Marinou, K ^a   Koumallos, N ^a   Papageorgiou, N ^a   Stefanadi, E ^a   Siasos, G ^a   Stefanadis, C ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Acute myocardial infarction; Coronary artery disease; Inflammation; sCD40L; Thrombosis

Indexed keywords

CD40 LIGAND; CYTOKINE; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; VASCULAR CELL ADHESION MOLECULE 1;

ACUTE HEART INFARCTION; ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORRELATION ANALYSIS; CYTOKINE PRODUCTION; DIABETES MELLITUS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; MALE; MOLECULAR INTERACTION; PARAMETER; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SMOKING;

ANALYSIS OF VARIANCE; CASE-CONTROL STUDIES; CD40 LIGAND; CORONARY ARTERY DISEASE; CORONARY THROMBOSIS; CYTOKINES; FEMALE; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PROSPECTIVE STUDIES;

EID: 34447343846     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2007.01834.x     Document Type: Article

References (41)

1. Davies MJ. Stability and instability: the two faces of coronary atherosclerosis: the Paul Dudley White Lecture 1995. Circulation 1996 94 : 2013 20.
2. Rifai N, Ridker PM. High-sensitivity C-reactive protein: a novel and promising marker of coronary heart disease. Clin Chem 2001 47 : 403 11.
3. Virmani R, Burke AP, Farb A, Kolodgie FD. Pathology of the unstable plaque. Prog Cardiovasc Dis 2002 44 : 349 56.
4. Van der Wal AC, Becker AE, van der Loos CM, Das PK. Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque moprhology. Circulation 1994 89 : 36 44.
5. Apple FS, Wu AHB, Mair J, Ravkilde J, Panteghini M, Tate J et al. Future biomarkers for detection of ischemia and risk stratification in acute coronary syndrome. Clin Chem 2005 51 : 810 24.
6. Liao JK. Endothelium and acute coronary syndromes. Clin Chem 1998 44 : 1799 808.
7. Urbich C, Dernbach E, Aicher A, Zeiher AM, Dimmeler S. CD40 ligand inhibits endothelial cell migration by increasing production of endothelial reactive oxygen species. Circulation 2002 106 : 981 6.
8. Schonbeck U, Libby P. The CD40/CD154 receptor/ligand dyad. Cell Mol Life Sci 2001 58 : 4 43.
9. Henn V, Slupsky JR, Grafe M, Anagnostopoulos I, Forster R, Berghaus G et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 1998 391 : 591 4.
10. Aukrust P, Muller F, Ueland T, Berget T, Aaser E, Brunsvig A et al. Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina: possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes. Circulation 1999 100 : 614 20.
11. Andre P, Prasad KS, Denis CV, He M, Papalia JM, Hynes RO et al. CD40L stabilizes arterial thrombi by a β3 integrin-dependent mechanism. Nat Med 2002 8 : 247 52.
12. Mach F, Schonbeck U, Sukhova GK, Bourcier T, Bonnefoy JY, Pober JS et al. Functional CD40 ligand is expressed on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for CD40-CD40 ligand signaling in atherosclerosis. Proc Natl Acad Sci USA 1997 94 : 1931 6.
13. Hollenbaugh D, Grosmaire LS, Kullas CD, Chalupny NJ, Braesch-Andersen S, Noelle RJ et al. The human T cell antigen gp39, a member of the TNF gene family, is a ligand for the CD40 receptor: expression of a soluble form of gp39 with B cell co-stimulatory activity. EMBO J 1992 11 : 4313 21.
14. Grewal IS, Flavell RA. The CD40 ligand. Immunol Res 1997 16 : 59 70.
15. André P, Nannizzi-Alaimo L, Prasad SK, Phillips DR. Platelet-derived CD40L: the switch-hitting player of cardiovascular disease. Circulation 2002 106 : 896 9.
16. Burke AP, Farb A, Malcom GT, Liang Y, Smialek J, Virmani R. Effect of risk factors on the mechanism of acute thrombosis and sudden coronary death in women. Circulation 1998 97 : 2110 6.
17. Schonbeck U, Varo N, Libby P, Buring J, Ridker PM. Soluble CD40L and cardiovascular risk in women. Circulation 2001 104 : 2266 8.
18. Heeschen C, Dimmeler S, Hamm CW, van den Brand MJ, Boersma E, Zeiher AM et al. Soluble CD40 ligand in acute coronary syndromes. N Engl J Med 2003 348 : 1104 11.
19. Blake GJ, Ostfeld RJ, Yucel EK, Varo N, Schonbeck U, Blake MA et al. Soluble CD40 ligand levels indicate lipid accumulation in carotid atheroma: an in vivo study with high-resolution MRI. Arterioscler Thromb Vasc Biol 2003, 23 : e11 4.
20. Yan J, Wu Z, Huang Z, Li L, Zhong R, Kong X. Clinical Implications of increased expression of CD40L in patients with acute coronary syndromes. Chin Med J 2002 115 : 491 3.
21. Alpert JS, Thygesen K, Antman E, Bassand JP. Myocardial infarction redefined - a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol 2000 36 : 959 69.
22. Antman EM, Anbe DT, Armstrong PW, Bates ER, Green LA, Hand M et al. American College of Cardiology; American Heart Association Task Force on Practice Guidelines; Canadian Cardiovascular Society, ACC/AHA Guidelines for the Management of Patients with ST-Elevation Myocardial Infarction: a Report of the American College Of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction). Circulation 2004 110 : e82 292.
23. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diab Care 2006 29 : S43 8.
24. McPherson R, Frohlich J, Fodor G, Genest J. Canadian cardiovascular society position statement-recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease. Can J Cardiol 2006 22 : 913 27.
25. European Society of Hypertension-European Society of Cardiology Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003 21 : 1011 53.
26. Kostner KM. Activation of the complement system: a crucial link between inflammation and atherosclerosis? Eur J Clin Invest 2004 34 : 800 2.
27. Li H, Cybulsky MI, Gimbrone MA, Libby P. Inducible expression of vascular cell adhesion molecule-1 by vascular smooth muscle cells in vitro and within rabbit atheroma. Am J Pathol 1993 143 : 1551 9.
28. Pai JK, Pischon T, Ma J, Manson JE, Hankinson SE, Joshipura K et al. Inflammatory markers and the risk of coronary heart disease in men and women. N Engl J Med 2004 351 : 2599 610.
29. Antoniades C, Tousoulis D, Vasiliadou C, Stefanadi E, Marinou K, Stefanadis C. Genetic polymorphisms of platelet glycoprotein Ia and the risk for premature myocardial infarction. Effects on the release of sCD40L during the acute phase of premature myocardial infarction. J Am Coll Cardiol 2006 47 : 1959 66.
30. Gawaz M. Role of platelets in coronary thrombosis and reperfusion of ischemic myocardium. Cardiovasc Res 2004 61 : 498 511.
31. Lutgens E, Gorelik L, Daemen MJ, de Muinck ED, Grewal IS, Koteliansky VE et al. Requirement for CD154 in the progression of atherosclerosis. Nat Med 1999 5 : 1313.
32. Harding SA, Sarma J, Josephs DH, Cruden NL, Din JN, Twomey PJ et al. Upregulation of the CD40/CD40 ligand dyad and platelet-monocyte aggregation in cigarette smokers. Circulation 2004 109 : 1926 9.
33. Varo N, Vicent D, Libby P, Nuzzo R, Calle-Pascual AL, Bernal MR et al. Elevated plasma levels of the atherogenic mediator soluble CD40 ligand in diabetic patients: a novel target of thiazolidinediones. Circulation 2003 107 : 2664 9.
34. Garlichs CD, John S, Schmeisser A, Eskafi S, Stumpf C, Karl M et al. Upregulation of CD40 and CD40 ligand (CD154) in patients with moderate hypercholesterolemia. Circulation 2001 104 : 2395 400.
35. Li J, Zhao SP, Peng DQ, Xu ZM, Zhou HN. Early effect of pravastatin on serum soluble CD40L, matrix metalloproteinase-9, and C-reactive protein in patients with acute myocardial infarction. Clin Chem 2004 50 : 1696 9.
36. Ballantyne CM, Nambi V. Markers of inflammation and their clinical significance. Atheroscler Suppl 2005 6 : 21 9.
37. Danese S, Sans M, Scaldaferri F, Sgambato A, Rutella S, Cittadini A et al. TNF-α blockade down-regulates the CD40/CD40L pathway in the mucosal microcirculation: a novel anti-inflammatory mechanism of infliximab in Crohn's disease. J Immunol 2006 176 : 2617 24.
38. Ohashi Y, Kawashima S, Mori T, Terashima M, Ichikawa S, Ejiri J et al. Soluble CD40 ligand and interleukin-6 in the coronary circulation after acute myocardial infarction. Int J Cardiol 2006 112 : 52 8.
39. Smith-Norowitz TA, Shani J, Weiser W, Schulhoff N, Norowitz K, Lichstein E et al. Lymphocyte activation in angina pectoris. Clin Immunol 1999 93 : 168 75.
40. Libby P, Simon DI. Inflammation and thrombosis. The clot thickens. Circulation 2001 103 : 1718 20.
41. Gokulakrishnan K, Deepa R, Mohan V, Gross MT. Soluble P-selectin and CD40L levels in subjects with prediabetes, diabetes mellitus, and metabolic syndrome - the Chenna Urban Rural Epidemiology Study. Metab Clin Exp 2006 55 : 237 42.